HOOFDDORP, The Netherlands–(BUSINESS WIRE)–Bioventus,
a global leader in orthobiologic solutions, is launching DUROLANE,
its single-injection joint-fluid osteoarthritis (OA) treatment, in
Malaysia and has selected Athrotech
as its exclusive distribution partner for the market.
OA involves the breakdown, or degeneration, of cartilage and the
synovial fluid that cushions and lubricates joint tissues. It’s
estimated that up to 20% of the adult population of Malaysia suffers
from osteoarthritis and the most common form of OA in the country is
knee OA.1 Hyaluronic acid (HA)-based products like
DUROLANE, help manage pain in the knees and hips of patients with OA.
“Athrotech is a great fit for Bioventus as we continue to grow in Asia
and expand our reach with HA products like DUROLANE,” said Tony
Bihl, CEO of Bioventus. “Malaysia is the fourth market in Asia where
Bioventus has introduced DUROLANE, providing even more patients
and physicians access to a proven pain reliever for knee OA.”
“We’re passionate about technologies that minimize risk, time, are
helpful to patients and have uncompromising quality,” said Jeff Luah,
Director, Athrotech. “DUROLANE is safe, patient injections can be
done very quickly and it is a single injection product designed to
provide powerful and long-lasting knee pain relief.”
“Athrotech has experience in the orthopedic field associated with OA as
a disease state and we are pleased to offer them the exclusive
distribution rights to DUROLANE,” said John Nosenzo, Chief
Commercial Officer, Bioventus. “The market has a favorable mix of
private, payer and self-pay patients and we expect to grow our business
together for many years to come.”
DUROLANE is based on a natural, safe and proven technology
process called NASHA®. This process yields stabilized
(HA) which is a naturally occurring molecule that provides the
lubrication and cushioning in a normal joint. It has been proven to
provide greater reduction in OA knee pain versus Synvisc-One®2*
and longer lasting pain relief versus a steroid injection3. DUROLANE
is also safe for repeated courses of therapy. Repeated use of
DUROLANE does not increase the incidence of adverse events.4
Bioventus is an orthobiologics company that delivers clinically proven,
cost-effective products that help people heal quickly and safely. Its
mission is to make a difference by helping patients resume and enjoy
active lives. The orthobiologic products from Bioventus include
offerings for osteoarthritis, surgical and non-surgical bone healing.
Built on a commitment to high quality standards, evidence-based medicine
and strong ethical behavior, Bioventus is a trusted partner for
physicians worldwide. For more information, visit www.BioventusGlobal.com
and follow the company on Twitter @Bioventusglobal.
Bioventus, the Bioventus logo, and DUROLANE are registered trademarks of
Bioventus LLC. NASHA is a registered trademark of Nestle Skin Health.
Synvisc-One and Synvisc are registered trademarks of Genzyme Corporation.
Summary of Indication for Use: Symptomatic treatment of mild to
moderate knee or hip osteoarthritis. There are no known
contraindications. You should not use DUROLANE if you have infections or
skin disease at the injection site. DUROLANE has not been tested in
pregnant or lactating women, or children. Risks can include transient
pain, swelling and/or stiffness at the injection site. Indications
presented are those approved in Malaysia; indications and product
offerings vary by country. Consult with your local Bioventus
representative for approved use within your region of interest. Full
prescribing information can be found in product labeling, at www.DUROLANE.com.
References: 1. Arthritis Foundation of Malaysia website http://afm.org.my/wp/?p=77.
Updated 2015. Accessed November 1, 2018. 2. McGrath AF, McGrath
AM, Jessop ZM, et al. A comparison of intra-articular hyaluronic acid
competitors in the treatment of mild to moderate knee osteoarthritis. J
Arthritis. 2013; 2(1):108. doi:10.4172/2167-7921.1000108. 3. Leighton
R, Åkermark C, Therrien R, et. al. NASHA hyaluronic acid vs
methylprednisolone for knee osteoarthritis: a prospective, multi-centre,
randomized, non-inferiority trial. Osteoarthritis Cartilage.
2014; 22(1):17-25. 4. DUROLANE [package insert]. Durham, NC:
Bioventus LLC; 2017.
Thank you for donating to DutchNews.nl.
We could not provide the Dutch News service, and keep it free of charge, without the generous support of our readers. Your donations allow us to report on issues you tell us matter, and provide you with a summary of the most important Dutch news each day.Make a donation